CStone Pharmaceuticals
Qingmei Shi is the Chief Medical Officer at CStone Pharmaceuticals. Prior to this role, Qingmei served as Senior Vice President and Head of Clinical Development at the same company. Qingmei has an extensive background in medical monitoring, with experience as a Senior Medical Director at Covance and various roles at PAREXEL. Qingmei holds a PhD in Biology and medicine from the National University of Singapore, and a Doctor of Medicine in ENT oncology from ShanDong Medical University in China.
CStone Pharmaceuticals
CStone is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established at the end of 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. With a strategic emphasis on immuno-oncology combination therapies, the Company has built an oncology-focused pipeline of 16 drug candidates, including 5 late-stage candidates at pivotal trials or registration stages. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone’s vision is to become a world-renowned biopharmaceutical company that is leading the way to conquering cancer.